Last 12 months
Inside the activity.
0 purchase rows · 148 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 57 |
| Dec 2025 | 0 | 28 |
| Jan 2026 | 0 | 11 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 24 |
| Jun 2026 | 0 | 22 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 28, 2026 Filed Apr 29, 2026 23:16 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 95,412 | $0.73 | $69,650.76 |
DisclosureSEC source: 0001134657-26-000007 · form4-04292026_110444.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,010,508 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026. F6 · shares: The shares were sold as follows: 10,223 by AM LLC, 64,541 by BV 2014, 4,305 by BV 2014(B), 2,222 by AM BV2014 and 14,121 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.673 to $0.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 215,406 by AM LLC, 1,360,025 by BV 2014, 90,711 by BV 2014(B), 46,811 by AM BV2014 and 297,555 by MPM OIF. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 23:16 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 53,940 | $0.85 | $45,849.00 |
DisclosureSEC source: 0001134657-26-000007 · form4-04292026_110444.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,105,920 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026. F2 · shares: The shares were sold as follows: 5,779 by MPM Asset Management LLC ("AM LLC"), 36,488 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,434 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 1,256 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 7,983 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.818 to $0.8788 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 225,629 by AM LLC, 1,424,566 by BV 2014, 95,016 by BV 2014(B), 49,033 by AM BV2014 and 311,676 by MPM OIF. Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 21:07 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 38,782 | $0.54 | $20,942.28 |
DisclosureSEC source: 0001134657-26-000006 · form4-01202026_090141.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,159,860 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,152 by MPM Asset Management LLC ("AM LLC"), 26,213 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,749 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 893 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,775 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.535 to $0.5495 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 231,408 by AM LLC, 1,461,054 by BV 2014, 97,450 by BV 2014(B), 50,289 by AM BV2014 and 319,659 by MPM OIF. Read SEC document |
| January 15, 2026 Filed Jan 15, 2026 22:22 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 37,413 | $0.55 | $20,577.15 |
DisclosureSEC source: 0001134657-26-000005 · form4-01152026_100154.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,198,642 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 4,002 by AM LLC, 25,285 by BV 2014, 1,686 by BV 2014(B), 872 by AM BV2014 and 5,568 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5305 to $0.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 235,560 by AM LLC, 1,487,267 by BV 2014, 99,199 by BV 2014(B), 51,182 by AM BV2014 and 325,434 by MPM OIF. Read SEC document |
| January 14, 2026 Filed Jan 15, 2026 22:22 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 30,616 | $0.57 | $17,451.12 |
DisclosureSEC source: 0001134657-26-000005 · form4-01152026_100154.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,236,055 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 3,275 by AM LLC, 20,692 by BV 2014, 1,380 by BV 2014(B), 712 by AM BV2014 and 4,557 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5524 to $0.5857 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 239,562 by AM LLC, 1,512,552 by BV 2014, 100,885 by BV 2014(B), 52,054 by AM BV2014 and 331,002 by MPM OIF. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 22:22 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 43,198 | $0.55 | $23,758.90 |
DisclosureSEC source: 0001134657-26-000005 · form4-01152026_100154.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,266,671 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,621 by MPM Asset Management LLC ("AM LLC"), 29,195 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,947 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,006 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 6,429 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.53675 to $0.5697 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 242,837 by AM LLC, 1,533,244 by BV 2014, 102,265 by BV 2014(B), 52,766 by AM BV2014 and 335,559 by MPM OIF. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 22:09 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 58,980 | $0.57 | $33,618.60 |
DisclosureSEC source: 0001134657-26-000004 · form4-01122026_100138.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,309,869 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 6,309 by AM LLC, 39,861 by BV 2014, 2,659 by BV 2014(B), 1,373 by AM BV2014 and 8,778 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5608 to $0.606 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 247,458 by AM LLC, 1,562,439 by BV 2014, 104,212 by BV 2014(B), 53,772 by AM BV2014 and 341,988 by MPM OIF. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 22:09 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 24,678 | $0.61 | $15,053.58 |
DisclosureSEC source: 0001134657-26-000004 · form4-01122026_100138.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,368,849 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 2,640 by AM LLC, 16,678 by BV 2014, 1,112 by BV 2014(B), 575 by AM BV2014 and 3,673 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6019 to $0.6583 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 253,767 by AM LLC, 1,602,300 by BV 2014, 106,871 by BV 2014(B), 55,145 by AM BV2014 and 350,766 by MPM OIF. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:09 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 7,716 | $0.63 | $4,861.08 |
DisclosureSEC source: 0001134657-26-000004 · form4-01122026_100138.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,393,527 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 825 by MPM Asset Management LLC ("AM LLC"), 5,215 by MPM BioVentures 2014, L.P. ("BV 2014"), 348 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 180 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 1,148 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6243 to $0.6368 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 256,407 by AM LLC, 1,618,978 by BV 2014, 107,983 by BV 2014(B), 55,720 by AM BV2014 and 354,439 by MPM OIF. Read SEC document |
| January 07, 2026 Filed Jan 7, 2026 22:12 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 11,915 | $0.64 | $7,625.60 |
DisclosureSEC source: 0001134657-26-000002 · form4-01072026_100145.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,401,243 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 1,275 by AM LLC, 8,053 by BV 2014, 537 by BV 2014(B), 277 by AM BV2014 and 1,773 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6276 to $0.6598 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 257,232 by AM LLC, 1,624,193 by BV 2014, 108,331 by BV 2014(B), 55,900 by AM BV2014 and 355,587 by MPM OIF. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 22:12 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 40,761 | $0.65 | $26,494.65 |
DisclosureSEC source: 0001134657-26-000002 · form4-01072026_100145.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,413,158 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 4,361 by AM LLC, 27,548 by BV 2014, 1,837 by BV 2014(B), 948 by AM BV2014 and 6,067 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.64 to $0.6599 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 258,507 by AM LLC, 1,632,246 by BV 2014, 108,868 by BV 2014(B), 56,177 by AM BV2014 and 357,360 by MPM OIF. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 22:12 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 18,378 | $0.64 | $11,761.92 |
DisclosureSEC source: 0001134657-26-000002 · form4-01072026_100145.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,453,919 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 1,966 by MPM Asset Management LLC ("AM LLC"), 12,420 by MPM BioVentures 2014, L.P. ("BV 2014"), 828 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 429 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,735 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.63435 to $0.6549 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 262,868 by AM LLC, 1,659,794 by BV 2014, 110,705 by BV 2014(B), 57,125 by AM BV2014 and 363,427 by MPM OIF. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 22:32 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 18,568 | $0.63 | $11,697.84 |
DisclosureSEC source: 0001134657-26-000001 · form4-01022026_100128.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,472,297 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 1,986 by AM LLC, 12,549 by BV 2014, 837 by BV 2014(B), 432 by AM BV2014 and 2,764 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.62 to $0.6499 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 264,834 by AM LLC, 1,672,214 by BV 2014, 111,533 by BV 2014(B), 57,554 by AM BV2014 and 366,162 by MPM OIF. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 22:32 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 24,962 | $0.62 | $15,476.44 |
DisclosureSEC source: 0001134657-26-000001 · form4-01022026_100128.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,490,865 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 2,670 by AM LLC, 16,870 by BV 2014, 1,125 by BV 2014(B), 582 by AM BV2014 and 3,715 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6038 to $0.6359 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 266,820 by AM LLC, 1,684,763 by BV 2014, 112,370 by BV 2014(B), 57,986 by AM BV2014 and 368,926 by MPM OIF. Read SEC document |
| December 30, 2025 Filed Jan 2, 2026 22:32 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 34,847 | $0.61 | $21,256.67 |
DisclosureSEC source: 0001134657-26-000001 · form4-01022026_100128.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,515,827 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 3,728 by MPM Asset Management LLC ("AM LLC"), 23,551 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,571 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 811 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,186 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6085 to $0.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 269,490 by AM LLC, 1,701,633 by BV 2014, 113,495 by BV 2014(B), 58,568 by AM BV2014 and 372,641 by MPM OIF. Read SEC document |
| December 29, 2025 Filed Dec 29, 2025 22:27 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 108,606 | $0.61 | $66,249.66 |
DisclosureSEC source: 0001134657-25-000018 · form4-12292025_101245.xml · nonDerivative · entry 5 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,550,674 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F15 · shares: The shares were sold as follows: 11,618 by AM LLC, 73,401 by BV 2014, 4,896 by BV 2014(B), 2,526 by AM BV2014 and 16,165 by MPM OIF. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.58955 to $0.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F17 · ownership.nature: The shares are held as follows: 273,218 by AM LLC, 1,725,184 by BV 2014, 115,066 by BV 2014(B), 59,379 by AM BV2014 and 377,827 by MPM OIF. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 22:27 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 35,632 | $0.63 | $22,448.16 |
DisclosureSEC source: 0001134657-25-000018 · form4-12292025_101245.xml · nonDerivative · entry 4 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,659,280 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F12 · shares: The shares were sold as follows: 3,812 by AM LLC, 24,082 by BV 2014, 1,606 by BV 2014(B), 829 by AM BV2014 and 5,303 by MPM OIF. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6165 to $0.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F14 · ownership.nature: The shares are held as follows: 284,836 by AM LLC, 1,798,585 by BV 2014, 119,962 by BV 2014(B), 61,905 by AM BV2014 and 393,992 by MPM OIF. Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 22:27 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 16,310 | $0.65 | $10,601.50 |
DisclosureSEC source: 0001134657-25-000018 · form4-12292025_101245.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,694,912 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 1,745 by AM LLC, 11,023 by BV 2014, 735 by BV 2014(B), 379 by AM BV2014 and 2,428 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6337 to $0.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 288,648 by AM LLC, 1,822,667 by BV 2014, 121,568 by BV 2014(B), 62,734 by AM BV2014 and 399,295 by MPM OIF. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 22:27 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 71,428 | $0.63 | $44,999.64 |
DisclosureSEC source: 0001134657-25-000018 · form4-12292025_101245.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,711,222 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 7,641 by AM LLC, 48,274 by BV 2014, 3,220 by BV 2014(B), 1,662 by AM BV2014 and 10,631 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.61 to $0.6728 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 290,393 by AM LLC, 1,833,690 by BV 2014, 122,303 by BV 2014(B), 63,113 by AM BV2014 and 401,723 by MPM OIF. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 22:27 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 59,307 | $0.69 | $40,921.83 |
DisclosureSEC source: 0001134657-25-000018 · form4-12292025_101245.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,782,650 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 6,344 by MPM Asset Management LLC ("AM LLC"), 40,082 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,673 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,381 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 8,827 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6596 to $0.7341 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 298,034 by AM LLC, 1,881,964 by BV 2014, 125,523 by BV 2014(B), 64,775 by AM BV2014 and 412,354 by MPM OIF. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 23:28 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 9,983 | $1.14 | $11,380.62 |
DisclosureSEC source: 0001134657-25-000017 · form4-12172025_111249.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,841,957 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 1,068 by AM LLC, 6,747 by BV 2014, 450 by BV 2014(B), 232 by AM BV2014 and 1,486 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.095 to $1.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 304,378 by AM LLC, 1,922,046 by BV 2014, 128,196 by BV 2014(B), 66,156 by AM BV2014 and 421,181 by MPM OIF. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 23:28 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 14,548 | $1.05 | $15,275.40 |
DisclosureSEC source: 0001134657-25-000017 · form4-12172025_111249.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,851,940 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 1,556 by AM LLC, 9,832 by BV 2014, 656 by BV 2014(B), 339 by AM BV2014 and 2,165 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 305,446 by AM LLC, 1,928,793 by BV 2014, 128,646 by BV 2014(B), 66,388 by AM BV2014 and 422,667 by MPM OIF. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 23:28 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 23,640 | $1.07 | $25,294.80 |
DisclosureSEC source: 0001134657-25-000017 · form4-12172025_111249.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,866,488 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 2,529 by MPM Asset Management LLC ("AM LLC"), 15,977 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,066 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 550 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 3,518 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 307,002 by AM LLC, 1,938,625 by BV 2014, 129,302 by BV 2014(B), 66,727 by AM BV2014 and 424,832 by MPM OIF. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 22:32 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 17,858 | $1.08 | $19,286.64 |
DisclosureSEC source: 0001134657-25-000016 · form4-12122025_101227.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,890,128 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 1,910 by AM LLC, 12,069 by BV 2014, 805 by BV 2014(B), 416 by AM BV2014 and 2,658 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.06 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 309,531 by AM LLC, 1,954,602 by BV 2014, 130,368 by BV 2014(B),67,277 by AM BV2014 and 428,350 by MPM OIF. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 22:32 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 28,009 | $1.07 | $29,969.63 |
DisclosureSEC source: 0001134657-25-000016 · form4-12122025_101227.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,907,986 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 2,996 by AM LLC, 18,930 by BV 2014, 1,263 by BV 2014(B), 651 by AM BV2014 and 4,169 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.045 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 311,441 by AM LLC, 1,966,671 by BV 2014, 131,173 by BV 2014(B), 67,693 by AM BV2014 and 431,008 by MPM OIF. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 22:32 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 37,104 | $1.06 | $39,330.24 |
DisclosureSEC source: 0001134657-25-000016 · form4-12122025_101227.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,935,995 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 3,969 by MPM Asset Management LLC ("AM LLC"), 25,077 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,673 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 863 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,522 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9742 to $1.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 314,437 by AM LLC, 1,985,601 by BV 2014, 132,436 by BV 2014(B), 68,344 by AM BV2014 and 435,177 by MPM OIF. Read SEC document |
| December 09, 2025 Filed Dec 9, 2025 22:07 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 44,570 | $1.01 | $45,015.70 |
DisclosureSEC source: 0001134657-25-000015 · form4-12092025_101231.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,973,099 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 4,768 by AM LLC, 30,123 by BV 2014, 2,009 by BV 2014(B), 1,036 by AM BV2014 and 6,634 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.99 to $1.025 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 318,406 by AM LLC, 2,010,678 by BV 2014, 134,109 by BV 2014(B), 69,207 by AM BV2014 and 440,699 by MPM OIF. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 22:07 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 34,041 | $0.99 | $33,700.59 |
DisclosureSEC source: 0001134657-25-000015 · form4-12092025_101231.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,017,669 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 3,642 by AM LLC, 23,006 by BV 2014, 1,534 by BV 2014(B), 792 by AM BV2014 and 5,067 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9582 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 323,174 by AM LLC, 2,040,801 by BV 2014, 136,118 by BV 2014(B), 70,243 by AM BV2014 and 447,333 by MPM OIF. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 22:07 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 16,568 | $0.97 | $16,070.96 |
DisclosureSEC source: 0001134657-25-000015 · form4-12092025_101231.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,051,710 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 1,772 by MPM Asset Management LLC ("AM LLC"), 11,197 by MPM BioVentures 2014, L.P. ("BV 2014"), 747 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 386 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,466 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9434 to $0.9863 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 326,816 by AM LLC, 2,063,807 by BV 2014, 137,652 by BV 2014(B), 71,035 by AM BV2014 and 452,400 by MPM OIF. Read SEC document |
| December 04, 2025 Filed Dec 4, 2025 23:18 UTC |
GADICKE ANSBERTFormer 10% Owner
MPM ONCOLOGY INNOVATIONS FUND LPFormer 10% Owner
UBS Oncology Impact Fund L.P.Former 10% Owner
Oncology Impact Fund (Cayman) Management L.P.Former 10% Owner
MPM BIOIMPACT LLCFormer 10% Owner
MPM Oncology Innovations Fund GP LLCFormer 10% Owner
MPM ASSET MANAGEMENT LLCFormer 10% Owner
|
SaleCommon Stock | 83,230 | $0.97 | $80,733.10 |
DisclosureSEC source: 0001231919-25-000574 · form4-12042025_111237.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Former 10% Owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · Former 10% Owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · Former 10% Owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · Former 10% Owner MPM BioImpact LLC · CIK 0001687078 · Former 10% Owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · Former 10% Owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,784,111 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology. Read SEC document |
| December 04, 2025 Filed Dec 4, 2025 23:20 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 53,416 | $0.97 | $51,813.52 |
DisclosureSEC source: 0001134657-25-000014 · form4-12042025_111226.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,068,278 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014 and 7,950 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014 and 454,866 by MPM OIF. Read SEC document |
| December 04, 2025 Filed Dec 4, 2025 23:19 UTC |
MPM BioVentures 2014, L.P.Former 10% Owner
MPM BioVentures 2014 (B), L.P.Former 10% Owner
MPM BioVentures 2014 LLCFormer 10% Owner
MPM BioVentures 2014 GP LLCFormer 10% Owner
MPM Asset Management Investors BV2014 LLCFormer 10% Owner
|
SaleCommon Stock | 83,230 | $0.97 | $80,733.10 |
DisclosureSEC source: 0001231919-25-000575 · form4-12042025_111239.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · Former 10% Owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · Former 10% Owner MPM BioVentures 2014 LLC · CIK 0001765021 · Former 10% Owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · Former 10% Owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,784,111 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 23:18 UTC |
GADICKE ANSBERTFormer 10% Owner
MPM ONCOLOGY INNOVATIONS FUND LPFormer 10% Owner
UBS Oncology Impact Fund L.P.Former 10% Owner
Oncology Impact Fund (Cayman) Management L.P.Former 10% Owner
MPM BIOIMPACT LLCFormer 10% Owner
MPM Oncology Innovations Fund GP LLCFormer 10% Owner
MPM ASSET MANAGEMENT LLCFormer 10% Owner
|
SaleCommon Stock | 57,225 | $0.87 | $49,785.75 |
DisclosureSEC source: 0001231919-25-000574 · form4-12042025_111237.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Former 10% Owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · Former 10% Owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · Former 10% Owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · Former 10% Owner MPM BioImpact LLC · CIK 0001687078 · Former 10% Owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · Former 10% Owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,867,341 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 23:20 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 36,726 | $0.87 | $31,951.62 |
DisclosureSEC source: 0001134657-25-000014 · form4-12042025_111226.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,121,694 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014 and 5,466 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014 and 462,816 by MPM OIF. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 23:19 UTC |
MPM BioVentures 2014, L.P.Former 10% Owner
MPM BioVentures 2014 (B), L.P.Former 10% Owner
MPM BioVentures 2014 LLCFormer 10% Owner
MPM BioVentures 2014 GP LLCFormer 10% Owner
MPM Asset Management Investors BV2014 LLCFormer 10% Owner
|
SaleCommon Stock | 57,225 | $0.87 | $49,785.75 |
DisclosureSEC source: 0001231919-25-000575 · form4-12042025_111239.xml · nonDerivative · entry 2 MPM BioVentures 2014, L.P. · CIK 0001609492 · Former 10% Owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · Former 10% Owner MPM BioVentures 2014 LLC · CIK 0001765021 · Former 10% Owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · Former 10% Owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,867,341 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 23:18 UTC |
GADICKE ANSBERTFormer 10% Owner
MPM ONCOLOGY INNOVATIONS FUND LPFormer 10% Owner
UBS Oncology Impact Fund L.P.Former 10% Owner
Oncology Impact Fund (Cayman) Management L.P.Former 10% Owner
MPM BIOIMPACT LLCFormer 10% Owner
MPM Oncology Innovations Fund GP LLCFormer 10% Owner
MPM ASSET MANAGEMENT LLCFormer 10% Owner
|
SaleCommon Stock | 59,277 | $0.89 | $52,756.53 |
DisclosureSEC source: 0001231919-25-000574 · form4-12042025_111237.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Former 10% Owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · Former 10% Owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · Former 10% Owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · Former 10% Owner MPM BioImpact LLC · CIK 0001687078 · Former 10% Owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · Former 10% Owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,924,566 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 23:20 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 38,043 | $0.89 | $33,858.27 |
DisclosureSEC source: 0001134657-25-000014 · form4-12042025_111226.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,158,420 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014 and 468,282 by MPM OIF. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 23:19 UTC |
MPM BioVentures 2014, L.P.Former 10% Owner
MPM BioVentures 2014 (B), L.P.Former 10% Owner
MPM BioVentures 2014 LLCFormer 10% Owner
MPM BioVentures 2014 GP LLCFormer 10% Owner
MPM Asset Management Investors BV2014 LLCFormer 10% Owner
|
SaleCommon Stock | 59,277 | $0.89 | $52,756.53 |
DisclosureSEC source: 0001231919-25-000575 · form4-12042025_111239.xml · nonDerivative · entry 1 MPM BioVentures 2014, L.P. · CIK 0001609492 · Former 10% Owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · Former 10% Owner MPM BioVentures 2014 LLC · CIK 0001765021 · Former 10% Owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · Former 10% Owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,924,566 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology. Read SEC document |
| December 01, 2025 Filed Dec 1, 2025 23:11 UTC |
GADICKE ANSBERT10% owner
MPM ONCOLOGY INNOVATIONS FUND LP10% owner
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
MPM Oncology Innovations Fund GP LLC10% owner
MPM ASSET MANAGEMENT LLC10% owner
|
SaleCommon Stock | 60,917 | $0.94 | $57,261.98 |
DisclosureSEC source: 0001231919-25-000564 · form4-12012025_111253.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,983,843 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014, 5,819 by MPM OIF and 21,821 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014, 473,944 by MPM OIF and 1,787,380 by UBS Oncology. Read SEC document |
| December 01, 2025 Filed Dec 1, 2025 23:13 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 39,096 | $0.94 | $36,750.24 |
DisclosureSEC source: 0001134657-25-000013 · form4-12012025_111233.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,196,463 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014 and 5,819 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014 and 473,944 by MPM OIF. Read SEC document |
| December 01, 2025 Filed Dec 1, 2025 23:12 UTC |
MPM BioVentures 2014, L.P.10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
|
SaleCommon Stock | 60,917 | $0.94 | $57,261.98 |
DisclosureSEC source: 0001231919-25-000565 · form4-12012025_111237.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,983,843 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014, 5,819 by MPM OIF and 21,821 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014, 473,944 by MPM OIF and 1,787,380 by UBS Oncology. Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 23:11 UTC |
GADICKE ANSBERT10% owner
MPM ONCOLOGY INNOVATIONS FUND LP10% owner
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
MPM Oncology Innovations Fund GP LLC10% owner
MPM ASSET MANAGEMENT LLC10% owner
|
SaleCommon Stock | 20,277 | $0.99 | $20,074.23 |
DisclosureSEC source: 0001231919-25-000564 · form4-12012025_111253.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,044,760 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014, 1,937 by MPM OIF and 7,263 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014, 479,763 by MPM OIF and 1,809,201 by UBS Oncology. Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 23:13 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 13,014 | $0.99 | $12,883.86 |
DisclosureSEC source: 0001134657-25-000013 · form4-12012025_111233.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,235,559 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014 and 1,937 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014 and 479,763 by MPM OIF. Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 23:12 UTC |
MPM BioVentures 2014, L.P.10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
|
SaleCommon Stock | 20,277 | $0.99 | $20,074.23 |
DisclosureSEC source: 0001231919-25-000565 · form4-12012025_111237.xml · nonDerivative · entry 2 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,044,760 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014, 1,937 by MPM OIF and 7,263 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014, 479,763 by MPM OIF and 1,809,201 by UBS Oncology Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 23:11 UTC |
GADICKE ANSBERT10% owner
MPM ONCOLOGY INNOVATIONS FUND LP10% owner
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
MPM Oncology Innovations Fund GP LLC10% owner
MPM ASSET MANAGEMENT LLC10% owner
|
SaleCommon Stock | 60,733 | $0.98 | $59,518.34 |
DisclosureSEC source: 0001231919-25-000564 · form4-12012025_111253.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,065,037 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,170 by MPM Asset Management LLC ("AM LLC"), 26,343 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,757 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 907 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,801 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,755 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014, 481,700 by MPM OIF and 1,816,464 by UBS Oncology. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 23:13 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 38,978 | $0.98 | $38,198.44 |
DisclosureSEC source: 0001134657-25-000013 · form4-12012025_111233.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,248,573 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,170 by MPM Asset Management LLC ("AM LLC"), 26,343 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,757 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 907 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,801 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014 and 481,700 by MPM OIF. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 23:12 UTC |
MPM BioVentures 2014, L.P.10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
|
SaleCommon Stock | 60,733 | $0.98 | $59,518.34 |
DisclosureSEC source: 0001231919-25-000565 · form4-12012025_111237.xml · nonDerivative · entry 1 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,065,037 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,170 by MPM Asset Management LLC ("AM LLC"), 26,343 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,757 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 907 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,801 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,755 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014, 481,700 by MPM OIF and 1,816,464 by UBS Oncology Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 23:03 UTC |
GADICKE ANSBERT10% owner
MPM ONCOLOGY INNOVATIONS FUND LP10% owner
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
MPM Oncology Innovations Fund GP LLC10% owner
MPM ASSET MANAGEMENT LLC10% owner
|
SaleCommon Stock | 42,533 | $0.92 | $39,130.36 |
DisclosureSEC source: 0001231919-25-000550 · form4-11252025_111145.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,125,770 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 2,920 by AM LLC, 18,449 by BV 2014, 1,230 by BV 2014(B), 635 by AM BV2014, 4,063 by MPM OIF and 15,236 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 352,045 by AM LLC, 2,223,199 by BV 2014, 148,284 by BV 2014(B), 76,522 by AM BV2014, 487,501 by MPM OIF and 1,838,219 by UBS Oncology. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 23:05 UTC |
EVNIN LUKEDirector
|
SaleCommon Stock | 27,297 | $0.92 | $25,113.24 |
DisclosureSEC source: 0001134657-25-000012 · form4-11252025_111121.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,287,551 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 2,920 by AM LLC, 18,449 by BV 2014, 1,230 by BV 2014(B), 635 by AM BV2014 and 4,063 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 352,045 by AM LLC, 2,223,199 by BV 2014, 148,284 by BV 2014(B), 76,522 by AM BV2014 and 487,501 by MPM OIF. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 23:04 UTC |
MPM BioVentures 2014, L.P.10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
|
SaleCommon Stock | 42,533 | $0.92 | $39,130.36 |
DisclosureSEC source: 0001231919-25-000551 · form4-11252025_111135.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,125,770 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 2,920 by AM LLC, 18,449 by BV 2014, 1,230 by BV 2014(B), 635 by AM BV2014, 4,063 by MPM OIF and 15,236 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 352,045 by AM LLC, 2,223,199 by BV 2014, 148,284 by BV 2014(B), 76,522 by AM BV2014, 487,501 by MPM OIF and 1,838,219 by UBS Oncology. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.